Shares of Vasogen Inc. tumbled more than 40 percent after the company said it was stopping the Phase III SIMPADICO trial of its Celacade technology in patients with symptomatic peripheral arterial disease (PAD). (BioWorld Today)

Shares of Vasogen Inc. tumbled more than 40 percent after the company said it was stopping the Phase III SIMPADICO trial of its Celacade technology in patients with symptomatic peripheral arterial disease (PAD). (BioWorld Today)